← Evidence map

ArticleClinical and molecular hepatology2024

Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on "Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy".

Junjie YuPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2024

this papercites it

Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on "Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy". | OpenQuestion